Hepatocellular carcinoma (HCC) carries a poor prognosis with no effective treatment available other than liver transplantation for selected patients. Vascular invasion of HCC is one of the most important negative predictor of survival. As the regulation of invasion of HCC cells is not well understood, our aim was to study the mechanisms by which galectin 3, a β-galactosidase binding lectin mediates HCC cell migration. HCC was induced by N-diethylnitrosamine (DEN) in wild type and galectin 3 −/− mice, and tumor formation, histology, and tumor cell invasion were assessed. The galectin 3 −/− mice developed significantly smaller tumor burden with a less invasive phenotype than the wild type animals. Galectin 3 was upregulated in the wild type HCC tumor tissue, but not in the surrounding parenchyma. Galectin 3 expression in HCC was induced by NF-κB transactivation as determined by chromatin immunoprecipitation assays. In vitro studies assessed the pro-migratory effects of galectin 3. The migration of hepatoma cells was significantly decreased after transfection by the galectin 3 siRNA and also after using the Rho kinase (ROCK) inhibitor Y-27632. The reorganization of the actin cytoskeleton, RhoA GTP ase activity and the phosphorylation of MLC2 were decreased in the galectin 3 siRNA-transfected cells. In addition, in vitro and in vivo evidence showed that galectin 3 deficiency reduced hepatoma cell proliferation and increased their apoptosis rate. In conclusion, galectin 3 is an important lectin that is induced in HCC cells, and promotes hepatoma cell motility and invasion by an autocrine pathway. Targeting galectin 3 therefore could be an important novel treatment strategy to halt disease progression.
Germany). The volumetric analysis was performed with the ASIPro VMsoftware (Concorde MicroSystems, Knoxville, TN).
Five wt and four galectin 3 −/− mice were included in this study. All procedures were reviewed and approved by the Animal Care Committee of the University of California Davis.
RNA interference
The immortalized mouse hepatoma cells Hepa1-6 (ATCC, Manassas, VA) were cultured in DMEM supplemented with 10% fetal bovine serum. The cells were maintained at 37°C in 5% CO 2 until the cells were 80% confluent, and then used for transfection.
SiRNA to galectin 3 (Santa Cruz Biotechnology, Santa Cruz, CA), or negative control scrambled siRNA (25nM, QIAGEN, Valencia, CA) was transfected into Hepa1-6 with RiboJuice transfection reagent (Novagen, Madison, WI), according to the manufacturer's instruction.
cDNA transfection
Hepa1-6 cells were transfected with the pCMX-IκBα phosphorylation mutant (kindly provided by S. Devaraj (Texas Children's Hospital, Houston, TX), originally from Addgene, pCMX-IkBα developed by Dr. Inder Verma (15) , or the control vector (transfection efficiency, 60-70%), using the GeneJuice Transfection reagent (Novagen), following the manufacturer's instruction.
Chromatin immunoprecipitation and quantitative PCR (ChIP-qPCR) Assay
NFκB binding sites within mouse Gal3 promoter (+200 ~ −2000bp) were identified by PROMO online (http://alggen.lsi.upc.es/cgi). ChIP was carried out as described previously (16) . After agarose gel electrophoresis and the product's size was confirmed with the average length 200-600 bp., rabbit anti-NFκB (p65) (Cell Signaling Technology, Beverly, MA) was used to pull down the transcription factor/DNA complex. Purified rabbit IgG (Santa Cruz Biotechnology Inc.) served as a control. Immunoprecipitated DNA was measured by qPCR for the respective NFκB binding sites using Power SYBR Green PCR master mix (Applied Biosystems, Foster City, CA). Primers were designed using Genscript online tool (https://www.genscript.com/ssl-bin/app/primer). A fragment (−205 to −137) adjacent to putative NFκB binding sites were amplified with primers: forward, 5′-GCAGGATGAGACCCTGACA-3′, and reverse, 5′-GACCGCACCCAGACTCTC-3′. For qPCR results, the relative gene expression profile was achieved by normalizing the ΔCt of targets to the Ct of IgG ChIP of each sample. The data were presented as fold enrichment.
Wound closure assay
The scrambled or galectin 3 siRNA-transfected Hepa1-6 cells were incubated in the presence or the absence of recombinant galectin 3 (1μM, provided by Dr. F-T Liu, UC Davis). After 48 hours of transfection, the cultures were scraped with a single-edged razor blade. Twenty four hours later, five microscopic fields were evaluated, and the number of cells migrating across the wound edge were determined in each field and calculated for each injury. In non-treated cells, migration was also assessed in the presence of Y-27632 (ROCK inhibitor, 10μM, Sigma, St Louis, MO). The experiments were repeated three times.
Immunohistochemistry and Immunofluorescence microscopy
The liver/tumor tissue was fixed in 4% buffered formalin and embedded in paraffin. H & E and reticulin staining were conducted by the department of pathology, UC Davis. The histology was analyzed by a hepatopathologist in a blinded fashion.
To detect galectin 3, the slides (4μm) were deparaffinized and rehydrated. For antigen retrieving, the slides were boiled in citrate buffer (0.01M, pH6.0). After incubated in 3% aqueous H 2 O 2 to ablate endogenous peroxidase, the sections were washed in 0.1% Triton X-100 and blocked with the reagents provided by the UltraVision Protein Block (Thermo Scientific, Rockford, IL). Sections were then sequentially incubated with primary antibody (galectin 3, 1:1000, kindly provided by Dr. F-T Liu (17) ; glypican 3, 1:100, Abcam, Cambridge, MA), secondary HRP conjugated antibody (1:500, Santa Cruz Biotechnology, CA). The slides were then treated with DAB Substrates (Abcam) to visualize the signal and counterstained with Mayer's hematoxylin. The vascular invasion was quantified in 5 fields in each animal.
Human HCC sections were obtained from the department of pathology, UC Davis. Sequential sections were processed for DAB staining to detect galectin 3/glypican 3, and galectin 3/NF-κB (p65) following the protocol described. NF-κB (p65) antibody (1:200) was purchased from Cell signaling Technology.
Cryostat sections from the frozen liver/tumor tissue, in consecutive sections to those slides with H & E staining were co-stained with anti-galectin 3 and F4/80 antibodies (1:200, eBioscience, San Diego, CA) followed by fluorescence labeled secondary antibodies (Life Technology). The images were analyzed by fluorescent microscopy to assess the colocalization of galectin 3 and F4/80. The galectin 3 + /F4/80 + cells were counted from 5 random views each slides. The cryostat sections were also probed with e-cadherin (1:500, BD Biosciences, San Jose, CA) to analyze the cell migratory activity. To assess the cell proliferation and apoptosis, Ki67 (Abcam) and active caspase-3 (1:500, Cell Signaling Technology) staining were performed. The positive cells in 5 fields were counted for each mouse.
To detect the cellular localization of RhoA, Hepa1-6 cells were transfected with scrambled or galectin 3 siRNA, fixed with 4% paraformaldehyde and permeabilized in 0.2% Triton X-100/PBS. After washing, they were blocked with 2% bovine serum albumin followed by incubating with anti-RhoA monoclonal antibody (1:40, Santa Cruz Biotechnology) for 16 hours at 4°C. The slides were then washed and incubated with rhodamine-conjugated phalloidin to visualize F-actin filaments. After washing, the secondary Alex Fluor 488-labeled anti-mouse IgG (1:1000, Life Technologies, Carlsbad, CA) was applied. The images were analyzed by fluorescence microscopy. Hepa1-6 cells transfected with scrambled or galectin 3 siRNA were treated with fas ligand (5ng/ml, 16 hours, Millipore, Billerica, MA), and stained for active caspase 3. The cell proliferation was evaluated by Ki67 staining.
RNA extraction and real-time RT-PCR
RNA was extracted from the cells or tissues using RNeasy Mini kit (QIAGEN) following the manufacturer's instruction. cDNA was synthesized using the iScript cDNA Synthesis kit (Bio-Rad, Hercules, CA). The SYBR Green DNA Master mix (Applied Biosystems,) was used for real-time PCR analysis (Life Technologies). The galectin-3 primers used were described previously (8) . For e-cadherin, the forward primer was 5′-CGAGAGAGTTACCCTACATA-3′ and the reverse, 5′-GTGTTGGGGGCATCATCATC-3′; for vimentin, forward, 5′-GCACCCTGCAGTCATTCAGA-3′ and reverse, 5′-CCACTTTCCGTTCAAGGTCAAG-3′.
Rho activation, pull-down assay
Tumor tissue or siRNA-transfected Hepa1-6 cells were lyzed and the supernatant was collected for the pull-down assay using a Rho activation assay kit (Millipore,). In brief, the cell lysates containing 1mg protein were mixed with glutathione-agarose beads bound with Rhotekin, containing a GTP-Rho binding domain. After incubation, the agarose beads were washed and collected by centrifugation, then resuspended in the sample buffer containing 1M dithiothreitol. The active GTP-Rho was released and denatured by boiling. The supernatant was collected and separated by SDS-polyacrylamide gel. The GTP-bound RhoA was detected by the antibody provided by the kit.
Western Blot analysis
Benign liver and tumor tissue was homogenized in RIPA buffer with protease inhibitor cocktails. The protein concentration was determined with the Bio-Rad protein assay kit (Thermo Scientific) and 20 μg of protein was separated by SDS-PAGE. The blot was probed with anti-galectin3 (kindly provided by Dr. F-T Liu, UC Davis) and anti-GAPDH (Trevigen, Gaithersburg, MD) as internal control. Hepa1-6 cells were transfected with scrambled or galectin3 siRNA, as above. Fifty μg of protein was used for Western blot. The blots were incubated with the appropriate antibodies for 16h at 4 C: anti-phospo-NFκB (p65) (Cell Signaling Techology), phospho MLC2 and MLC2 antibodies (Cell Signaling Technology), phospho-Akt and total Akt antibodies (Cell Signaling Technology) or the antigalectin 3 antibody. The membranes were incubated with horseradish peroxidase-conjugated secondary antibodies (Santa Cruz Biotechnology) and the blots were developed by enhanced chemiluminescence (Thermo Scientific, Rockford, IL). The intensity of signals was quantified with ImageJ (National Institutes of Health, Bethesda, MD). The data were normalized to the expression of anti-GAPDH antibody.
Statistical Analysis
The data shown represent at least three experiments and expressed as the mean ± SEM. Differences between groups were compared using one-way analysis of variance (ANOVA) associated with the Dunnett's test. Statistical significance was considered when p<0.05.
Results

Galectin 3 −/− mice have a decreased tumor burden and a less invasive phenotype of HCC
To study the role of galectin 3 in an in vivo model of HCC, the wild type and galectin 3 −/− mice were injected with DEN or corn oil at the age of 4 weeks to induce HCC. Micro-CT scans were performed after 52 weeks to assess tumor size by volumetric analysis. (Fig. 1Aa-d) . While in the wt mice the livers were largely replaced by tumors, the tumor burden in the galectin 3 −/− mice was significantly reduced (**p<0.01, Fig. 1B ). The liver tissues were harvested and processed for reticulin staining and glypican 3 immunohistochemistry staining to confirm the presence of HCC (Fig. 1C) . Both wt and galectin 3 −/− mice remarkably lost reticulin stains in the tumor area ( Fig. 1C a, b). They both were positive for another HCC marker glypican 3 ( Fig. 1C c, d ).
Based on the histological analysis ( Fig. 2A) , HCC from the wt mice exhibited more invasive properties with spindle-like cells and frequent vascular invasion (arrows). The tumors from the galectin 3 −/− mice exhibited a more differentiated, glandular phenotype, with histologically normal areas (nl) with portal tracts present. The vascular invasion foci were counted in five fields each animal (Fig. 2B ). Significantly less vascular invasion was observed in the galectin 3 −/− livers. The mRNA levels of e-cadherin and vimentin were assessed to further evaluate the invasive properties in these tumor tissues (Fig. 2C, D) . Wt tumors expressed significant lower level of e-cadherin (*p<0.05) and higher level of vimentin, suggesting an invasive phenotype compared to the knockout tumors. The ecadherin immunofluorescent staining also showed reduced e-cadherin in the wt tumor (Fig.  2 E) .
Fluorescent staining was also performed to detect Ki67 and active caspase 3 to assess the cell proliferation and apoptosis (Fig. 2F) . The positive cells were quantified as described. The wt tumor showed higher proliferation activity and lower apoptosis.
Galectin 3 is upregulated in HCC tumor cells and tumor associated macrophages
Next we examined the expression of galectin 3 in HCC. Sequential sections from human HCC were stained with galectin 3 and HCC marker glypican 3 (Fig. 3 A) . The galectin 3 positive areas were highly identical with the glypican 3 positive areas, indicating the correlation of galectin 3 and HCC. In mice (Fig. 3B) , galectin 3 was highly expressed in the DEN tumor, mainly in hepatoma cells; macrophages were positive as well (Fig. 3B, d , arrows). No galectin 3 signal was seen in normal hepatocytes (B, a). The induction of galectin 3 in HCC was then confirmed with Western blot analysis using benign and resected tumor tissues from the wt DEN mice (Fig. 3C, D) . The expression of galectin 3 was significantly higher in tumors than that in the surrounding parenchyma (***p<0.001). As tumor associated macrophages were shown to express galectin 3, consecutive sections were processed for H & E and immunofluorescent staining with galectin 3 and the macrophage marker F4/80 (Fig. 3F) . Beside the increased galectin 3 expression in the tumor cells, there were a significantly higher number of macrophages co-expressing galectin 3 and F4/80 (Fig.  3F , G b-g, arrowhead) in the tumor tissues compared to the surrounding stroma (**p<0.01).
Galectin 3 induction in hepatoma cells is mediated by NF-κB activation
To study the mechanism of galectin 3 upregulation in hepatoma cells, we focused on NF-κB, as the induction of NF-κB is a key event to the pathogenesis of HCC (18), and the promoter area of galectin 3 has been described to have NF-κB-responsive elements (8, 19, 20) . Sequential sections from human HCC were stained for galectin 3 and NF-κB (p65) (Fig. 4A) . The nuclear staining of p65 was observed in galectin 3 positive cells, suggesting the correlation of the activation of NF-κB signaling and galectin 3 expression in HCC. Next, tumor tissues and adjacent benign tissue from DEN-treated WT mice were processed for ChIP-qPCR assay to assess the transcriptional regulation of NF-κB on the galectin 3 promoter. The transactivation of NF-κB within the mouse galectin 3 promoter was significantly induced in the tumor tissues (Fig. 4B , *p<0.05). To corroborate our in vivo data we transfected Hepa1-6 cells with the pCMX-IκBα (phosphorylation mutant) vector to block the NF-κB signaling cascade, or a control vector. The PCR data showed that the galectin 3 expression decreased in the pCMX-IκBα-transfected cells (Fig. 4C , ***p<0.001), suggesting that NF-kB plays an important role in galectin 3 induction in HCC carcinogenesis. To compare the activation of NF-κB in wt and galectin 3 −/− tumors, the tissues were homogenized for Western blots to detect phospho-p65 (Fig. 4D, E ). The phospho-65 level was significantly less in the knockout tumors (*p<0.05).
Galectin 3 induces the migration of HCC cells
Because of the observed histological differences, and the smaller tumor burden in the galectin 3 −/− mice we postulated that galectin 3 modulates the invasive properties of HCC cells. Hepa1-6 cells were transfected with scrambled or galectin 3 siRNA, and scratch assay was performed. The galectin 3 siRNA -transfected cells showed a significantly lower migratory activity compared to the cells transfected with scrambled siRNA (Fig. 4A and B, **p<0.01). The inhibition of migration was partially reversed by recombinant galectin 3 ( Fig. 4A, d , and B, ***p<0.001), suggesting that extracellular galectin 3 is also involved in regulating HCC cell motility.
We also examined the proliferation and apoptosis rate of these cells (Fig. 5C-E) . The hepa1-6 cells expressing scrambled or galectin 3 siRNA were stained for Ki67. To evaluate the apoptosis, these cells were treated with fas ligand (FSL) prior the staining for active caspase 3. The Ki67 + cells were significantly reduced by galectin 3 siRNA (*p<0.05); and the active caspase 3 + cells were increased by galectin 3 silencing (**p<0.01). This confirmed our in vivo data that galectin 3 deficiency impaired cell proliferation and promoted apoptosis in mouse HCC (Fig. 2F ).
As cytoskeletal remodeling is crucial in cell migration, next we focused on the galectin 3-mediated regulation and recruitment of the RhoA GTPase to the leading edge, and the reorganization of the actin cytoskeleton. Hepa1-6 cells were transfected with scrambled or galectin 3 siRNA, and immunofluorescence microscopy was done to visualize F-actin filaments and RhoA (Fig. 6A) . The galectin 3 siRNA-transfected cells exhibited different morphology with a more rounded phenotype, whereas the non-transfected or scrambled siRNA transfected cells had elongated, fusiform morphology. RhoA and F-actin were colocalized to the leading edge in the non-transfected and scrambled siRNA transfected cells (arrows). In contrast, these signals were cytoplasmic in the cells expressing the galectin 3 siRNA. To study RhoA activation, a pull-down assay was done to assess the GTP-bound RhoA in galectin 3 or scrambled siRNA-transfected cells. RhoA GTPase activation was decreased after transfection with the galectin 3 siRNA (Fig. 6B , C, *p<0.05). The RhoA activation was also examined in vivo. The wt and the galectin 3 −/− tumor tissues were processed for the pull-down assay (Fig. 6D, E) . The galectin 3 −/− tumors showed a lower level of active RhoA.
HCC cell migration is Rho-kinase and MLCK mediated
Because Rho kinase (ROCK) is a downstream effector of RhoA in the regulation of cytoskeletal reorganization and cell motility, Hepa1-6 cells were incubated with Y-27632 (ROCK inhibitor), and migration was assessed by a wound closure assay. The cell migration was significantly inhibited by Y-27632 ( Fig. 7A and B, *p<0.05). The contraction of the actin cytoskeleton through activation of myosin 2 is essential in exerting force to induce the cells motility (21) . The actin-myosin 2 interaction is regulated by the phosphorylation of MLC2 on Ser-19 (22) . The regulatory light chains of the myosin 2 (MLC2) are known to be phosphorylated by the myosin light chain kinase (MLCK) as a downstream target of ROCK (22) . We found that in the galectin 3 siRNA-transfected Hepa1-6 cells, corresponding to the decrease in RhoA and ROCK activity; the phosphorylation of MLC2 was significantly reduced (Fig. 7C , D, *p<0.05).
Discussion
Tumor cell migration and locoregional invasion are characteristic features of HCC spread, and because of the lack of satisfactory treatment options, these histological findings herald a poor prognosis. Because the remodeling of the cytoskeleton is crucial in cell migration, and the Rho family of small GTPases are known to regulate the actin cytoskeleton, (23, 24) we have postulated that galectin 3 regulates and enhances RhoA activity in HCC tumor cells. Galectin 3 has been described to trigger signaling cascades by crosslinking with the glycan parts of the glycoconjugates (25), and we and others have shown that by binding to integrins it could elicit downstream signals affecting cytoskeletal reorganization and phagocytosis in hepatic stellate cells (8, 12 ). In the current study we sought to understand the mechanism by which galectin 3 controls tumor cell motility. We found that RhoA GTPase activation and downstream ROCK and MLC2 phosphorylation leading to actin reorganization were dependent on galectin 3. RhoA/ROCK activation were described earlier as correlating to the locoregional invasion of human HCC (26) , however the upstream regulators or cellular targets have not been fully evaluated. Discovering galectin 3 as a proximal inducer of the RhoA/ROCK pathway therefore could lead to novel therapeutic strategies. Targeting galectin 3 production or interfering with its ability to bind to the lattice could result in a less invasive phenotype, and a prolonged survival (27, 28) .
Whether the intra-or extra-cellular galectin 3 has a more dominant role in regulating cell motility is also an important question. In this study we mainly focused on the mechanistic aspects by which intracellular galectin 3 modulates invasiveness. Our data suggest that galectin 3 affects tumor cell migration by an autocrine process, as we found that galectin 3 was significantly induced in HCC cells, and siRNA targeting decreased the migratory activity. Nevertheless our data also suggest that galectin 3 produced in a paracrine manner likely by tumor associated macrophages can stimulate hepatoma cell motility possibly by affecting galectin 3/integrin crosslinking. The dominant cell type corresponding to the major source of galectin 3 production in HCC could be further studied in the future in cell specific knockout mice.
We have also tested the role of galectin 3 in vivo in the DEN-induced HCC model. The results indicated a decreased tumor burden, number of intrahepatic metastases, and a more differentiated tumor phenotype with the lack of vascular invasion in the galectin 3 −/− mice. HCC tumor cells and tumor associated macrophages were both positive for galectin 3. A plausible explanation for this is the induction of NF-κB transactivation, as we have shown in HCC tumor tissue and Hepa1-6 cells ( Figure 4 ). NF-κB induction is an important step in HCC tumorigenesis (29) (30) (31) , and its link to the increased HCC cell motility is well recognized (32, 33) . Galectin 3 induction of course can occur by other mechanisms as well, as it was shown that the epigenetic regulation of galectin 3 by β1 integrin induces cell motility (31) . Galectin 3 can also be involved in other regulatory pathways in cancer cell migration. The expression level of galectin 3 in colon cancer cells is correlated with cell migratory activity and this is mediated by K-Ras/Raf/Erk signaling (34) . Furthermore, as galectin 3 is a binding partner for β-catenin in immortalized breast cancer and colon cancer cells (35) , it could be involved in the regulation of Wnt/β-catenin signaling cascade in HCC.
In addition our in vitro and in vivo data showed that galectin 3 deficiency in hepatoma cells is correlated with decreased proliferative activity and increased apoptosis ( Figure 2F and Figure 5C ). These are in an agreement to the previous findings that galectin 3 promotes cells proliferation and protect cells from proapoptotic stimuli (36, 37) .
Galectin 3 plays an important role in liver fibrosis by inducing the activation of hepatic stellate cells and promoting the deposition of the extracellular matrix (7, 8) . We have previously shown that the active myofibroblasts and Kupffer cells secrete galectin 3 (8) . As the majority of HCCs arise in cirrhotic livers in humans, it is interesting to speculate that these cells beside tumor associated macrophages could also be important paracrine sources of galectin 3 in HCC tumorigenesis.
In summary, in this paper we have shown that galectin 3 promotes HCC cell migration, by inducing RhoA GTP-ase activity, MLC2 phosphorylation, and actin rearrangement required for a motile phenotype. In vivo galectin 3 −/− mice developed smaller tumor burden with a more differentiated phenotype in response to the carcinogen DEN. Development of therapeutic strategies targeting galectin 3 could prevent invasion and metastasis, and this in turn can lengthen a progression-free period that could bridge to liver transplantation. 
